Ther Deliv 2021 08 21;12(8):553-557. Epub 2021 Jul 21.
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Theranostics 2021 27;11(18):9107-9117. Epub 2021 Aug 27.
Department of Chemistry, Rice University, 6100 Main Street, Houston, Texas, 77005, USA.
Therapeutic antibody conjugates allow for the specific delivery of cytotoxic agents or immune cells to tumors, thus enhancing the antitumor activity of these agents and minimizing adverse systemic effects. Most current antibody conjugates are prepared by nonspecific modification of antibody cysteine or lysine residues, inevitably resulting in the generation of heterogeneous conjugates with limited therapeutic efficacies. Traditional strategies to prepare homogeneous antibody conjugates require antibody engineering or chemical/enzymatic treatments, processes that often affect antibody folding and stability, as well as yield and cost. Read More
Am J Clin Pathol 2021 Sep 14. Epub 2021 Sep 14.
Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
Objectives: Recent clinical trials have demonstrated significant clinical benefits from novel therapeutic compounds in breast cancer patient with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) score of 1+ or 2+ and negative in situ hybridization (ISH) result. A new concept of "HER2-low" breast cancer has been proposed and applied in the recent and ongoing clinical trials. In this article, we review the literature on the topic of HER2-low breast cancer. Read More
Anal Chem 2021 Sep 14. Epub 2021 Sep 14.
Spectroswiss, 1015 Lausanne, Switzerland.
The therapeutic efficacy and pharmacokinetics of antibody-drug conjugates (ADCs) in general, and antibody-oligonucleotide conjugates (AOCs) in particular, depend on the drug-to-antibody ratio (DAR) distribution and average value. The DAR is considered a critical quality attribute, and information pertaining to it needs to be gathered during ADC/AOC development, production, and storage. However, because of the high structural complexity of ADC/AOC samples, particularly in the initial drug-development stages, the application of the current state-of-the-art mass spectrometric approaches can be limited for DAR analysis. Read More
Bioconjug Chem 2021 Sep 14. Epub 2021 Sep 14.
Laboratory of Organic Chemistry, Wageningen University & Research, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
The availability of tools to generate homogeneous and stable antibody conjugates without recombinant DNA technology is a valuable asset in fields spanning from diagnostics to imaging and therapeutics. We present here a general approach for the conjugation to human IgG1 antibodies, by employing a straightforward two-stage protocol based on antibody deglycosylation followed by tyrosinase-mediated -quinone strain-promoted click chemistry. The technology is validated by the efficient and clean generation of highly potent DAR2 and DAR4 antibody-drug conjugates (ADCs) with cytotoxic payloads MMAE or PBD dimer, and their evaluation. Read More
Talanta 2021 Dec 8;235:122773. Epub 2021 Aug 8.
Department of Physical and Analytical Chemistry, Faculty of Chemistry, University of Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), C/ Julián Clavería 8, 33006, Oviedo, Spain. Electronic address:
The human epidermal growth factor receptor 2 (HER2) is a transmembrane protein that has become one of the most specific prognostic and predictive biomarker of breast cancer. Its early detection is key for optimizing the patient clinical outcome. This work is focused on the detection of HER2 in individual cells using an antibody containing lutetium (Lu) as reporter group that is monitored by introducing the individual cells into the inductively coupled plasma mass spectrometer (ICP-MS). Read More